Ó£»¨ÊÓÆµ

Skip to main content

Table 1 Baseline characteristics of study participants enrolled in UK Biobank according to CKM syndrome stages

From: Cardiovascular-kidney-metabolic syndrome modifies smoking-related risk for cardiovascular diseases: findings from an observational cohort study in UK Biobank

Characteristics

CKM syndrome

P value

CKM Stage 0

(N = 23,430)

CKM Stage 1

(N = 14,588)

CKM Stage 2

(N = 200,995)

CKM Stage 3

(N = 3,623)

Age, years, median (IQR)

51.00 (45.00, 58.00)

51.00 (45.00, 58.00)

58.00 (50.00, 63.00)

66.00 (63.00, 68.00)

 < 0.001

Sex, No. (%)

 M²¹±ô±ð

5541 (23.6)

4203 (28.8)

97,460 (48.5)

2818 (77.8)

 < 0.001

 F±ð³¾²¹±ô±ð

17,889 (76.4)

10,385 (71.2)

103,535 (51.5)

805 (22.2)

Ìý

Alcohol, No. (%)

 N±ð±¹±ð°ù

1256 (5.4)

757 (5.2)

11,599 (5.8)

374 (10.3)

 < 0.001

 D°ù¾±²Ô°ì±ð°ù

22,174 (94.6)

13,831 (94.8)

189,396 (94.2)

3249 (89.7)

Ìý

Physical activity level, No. (%)

 L´Ç·É

4300 (18.4)

3274 (22.4)

47,731 (23.7)

1099 (30.3)

 < 0.001

 M´Ç»å±ð°ù²¹³Ù±ð

12,222 (52.2)

7295 (50.0)

97,132 (48.3)

1591 (43.9)

Ìý

‽ö¾±²µ³ó

6908 (29.5)

4019 (27.6)

56,132 (27.9)

933 (25.8)

Ìý

Income, No. (%)

 Level 1

3136 (13.4)

2155 (14.8)

41,885 (20.8)

1505 (41.5)

 < 0.001

 Level 2

4739 (20.2)

3160 (21.7)

51,775 (25.8)

1149 (31.7)

Ìý

 Level 3

6558 (28.0)

4301 (29.5)

54,373 (27.1)

614 (16.9)

Ìý

 Level 4

8997 (38.4)

4972 (34.1)

52,962 (26.3)

355 (9.8)

Ìý

Employment, No. (%)

 W´Ç°ù°ì¾±²Ô²µ

17,956 (76.6)

11,179 (76.6)

123,589 (61.5)

968 (26.7)

 < 0.001

 U²Ô±ð³¾±è±ô´Ç²â±ð»å

268 (1.1)

196 (1.3)

2822 (1.4)

40 (1.1)

Ìý

 R±ð³Ù¾±°ù±ð»å

3551 (15.2)

2383 (16.3)

64,304 (32.0)

2467 (68.1)

Ìý

 O³Ù³ó±ð°ù

1655 (7.1)

830 (5.7)

10,280 (5.1)

148 (4.1)

Ìý

Education, No. (%)

 < 10 years

4995 (21.3)

3858 (26.4)

63,678 (31.7)

1723 (47.6)

 < 0.001

 ≥ 10 years

18,435 (78.7)

10,730 (73.6)

137,317 (68.3)

1900 (52.4)

Ìý

Diet, No. (%)

 < 5 portions/day

18,306 (78.1)

11,470 (78.6)

158,213 (78.7)

2847 (78.6)

0.232

 ≥ 5 portions/day

5124 (21.9)

3118 (21.4)

42,782 (21.3)

776 (21.4)

Ìý

Healthy sleep score, No. (%)

 0

20 (0.1)

25 (0.2)

441 (0.2)

14 (0.4)

 < 0.001

 1

540 (2.3)

543 (3.7)

9426 (4.7)

256 (7.1)

Ìý

 2

3297 (14.1)

2801 (19.2)

42,856 (21.3)

923 (25.5)

Ìý

 3

8468 (36.1)

5561 (38.1)

77,525 (38.6)

1378 (38.0)

Ìý

 4

8632 (36.8)

4464 (30.6)

57,731 (28.7)

872 (24.1)

Ìý

 5

2473 (10.6)

1194 (8.2)

13,016 (6.5)

180 (5.0)

Ìý

Smoking status, No. (%)

 N±ð±¹±ð°ù smoker

14,459 (61.7)

8262 (56.6)

109,182 (54.3)

1093 (30.2)

 < 0.001

 Former smoker

6693 (28.6)

4843 (33.2)

71,716 (35.7)

1390 (38.4)

Ìý

 Current smoker

2278 (9.7)

1483 (10.2)

20,097 (10.0)

1140 (31.5)

Ìý

Years since quitting (among former smokers), No. (%)

 ≥ 25

1208 (33.3)

877 (28.9)

18,102 (37.8)

503 (46.3)

 < 0.001

 15 to 24

1010 (27.9)

768 (25.3)

11,994 (25.0)

267 (24.6)

Ìý

 10 to 14

439 (12.1)

378 (12.5)

5320 (11.1)

100 (9.2)

Ìý

 5 to 9

455 (12.6)

449 (14.8)

6172 (12.9)

111 (10.2)

Ìý

 < 5

512 (14.1)

559 (18.4)

6348 (13.2)

106 (9.8)

Ìý
  1. Continuous variables were presented as mean (SD) or median (IQR), based on the result of normality assessment using the Shapiro–Wilk test. Categorical variables were presented as No. (%). Years since quitting was reported only among former smokers
  2. Abbreviations: N sample size, P P value, No. number of subjects, % percentage, SD standard deviation, IQR interquartile range, CVD cardiovascular disease, CKM cardiovascular-kidney-metabolic